Homozygous familial hypercholesterolemia (HoFH) in Canada
A Canadian registry reveals that even with multiple medications, severe inherited high cholesterol still carries significant heart attack risk, driving need for earlier intervention.
The Canadian HoFH Registry documents 67 patients with severe LDL-C elevation (median 13.53 mmol/L) receiving multi-drug lipid therapy including novel agents like evinacumab; one-fifth still experienced major cardiovascular events despite treatment. This real-world registry data highlights ongoing high cardiovascular risk and the need for earlier diagnosis and equitable access to approved therapies in this rare disease.
What the study was
- Study design
- Retrospective registry cohort study
- Population
- Canadian patients with clinical or genetic diagnosis of HoFH (Canadian HoFH Registry)
- Sample size
- 67
- Category
- Prevention
- Maturity
- Validated
- Journal
- Atherosclerosis
Why it surfaced
National registry data on a rare, ultra-high-risk lipid disorder; quantifies real-world treatment gap despite availability of novel agents (evinacumab, lomitapide). Unmet need remains high in this life-threatening rare disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.